Live Breaking News & Updates on Giant Cell Arteritis

Stay updated with breaking news from Giant cell arteritis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Targeting GM-CSF: A New Approach to COVID?


email article
Treatment with the investigational monoclonal antibody mavrilimumab significantly improved outcomes among patients with severe COVID-19 also given standard of care treatment, an international phase II randomized trial found.
Among patients who were not on mechanical ventilation at the time of study enrollment, but had severe COVID-19 with hyperinflammation, those given one of two doses of mavrilimumab had a 65% lower risk of mechanical ventilation or death by day 29, reported Lara Pupim, MD, of Kiniksa Pharmaceuticals in Lexington, Massachusetts.
Compared with patients given placebo, those on mavrilimumab also had a 61% reduction in risk of death at day 29, she reported during a late-breaking session of the European League Against Rheumatism virtual meeting. ....

South Africa , United States , Nancy Walsh , Lara Pupim , National Institute Of Allergy , Regina College In Newport , Kiniksa Pharmaceuticals In Lexington , Peuropean League Against Rheumatism , Kiniksa Pharmaceuticals , National Institute , Infectious Diseases , Salve Regina College , League Against , Gm Csf , Covid 19 , Mechanical Ventilation , Giant Cell Arteritis , ஒன்றுபட்டது மாநிலங்களில் , நான்சி வால்ஷ் , தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை , ரெஜினா கல்லூரி இல் நியூபோர்ட் , ஐரோப்பிய லீக் எதிராக வாத நோய் , தேசிய நிறுவனம் , தொற்று நோய்கள் , சால்வ் ரெஜினா கல்லூரி , லீக் எதிராக ,